lthough most modern corneal refractive surgery patients achieve extraordinary visual outcomes and serious complications are rare, it is critical that we focus more attention on developing methods and technologies to help those patients who have suffered complications and currently may be thought to have limited options for their repair. This was the main driving force behind the foundation of the Therapeutic Refractive Surgery section.
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We hope that by providing a rigorous scientific forum for developing technology and reporting such cases, we can foster increased development speed of new techniques, expand the group of surgeons interested in treating patients with corneal irregularities, and realize the final goal, which is to be able to fix any rare complication that could arise.
There are now several different treatment options for therapeutic refractive surgery, meaning that virtually all refractive surgery complications can be resolved, or at least the visual quality can be improved. Topographyguided custom ablation provides an effective solution for regularly irregular astigmatism, such as decentration and small optical zone, and transepithelial phototherapeutic keratectomy (PTK) provides a treatment option in even the most irregular corneas-as demonstrated by articles recently published in the Therapeutic Refractive Surgery section of this Journal. [2] [3] [4] [5] [6] [7] [8] These procedures have now matured to the point where they should become part of mainstream refractive surgery; all surgeons should at least be aware of these and feel comfortable in referring patients to specialist therapeutic centers if they do not have the tools available.
There are research groups working on more advanced therapeutic solutions, but these tend to be small in scale, being run by therapeutic sub-sub-specialists, and have been largely ignored by industry due to the low potential return on investment. As an analogy, even though most drivers will never use the airbags in our cars, few today would consider buying a car without them. We should be able to offer refractive surgery "with airbags," meaning the full ability to improve the outcome even if the rarest of complications arise. For this reason, the refractive surgery community needs to rally round to encourage industry to place greater value on therapeutic treatment options and make these available as part of the base package, rather than as an expensive add-on.
This situation is particularly exaggerated in the United States due to the U.S. Food and Drug Administration (FDA) regulatory process. The FDA requires manufacturers to undergo an expensive premarket approval process prior to commercializing a medical device, involving clinical studies with large sample sizes to demonstrate safety and effectiveness. This requirement also applies to significant improvements made to devices that have already received FDA approval. As a result, excimer lasers that have been in the U.S. market for more than a decade are still restricted from being used for therapeutic topography-guided treatments or for PTK, even though these treatments have been successfully performed outside the United States for more than 15 years.
Regulatory approval requires manufacturers to administer and fund the clinical trials. When the approval process is anticipated to cost more than the potential market will justify, manufacturers often decide not to participate. As a result, many excellent products never reach the U.S. market-a sad irony that results in the FDA effectively withholding important treatments from the very population it is chartered to protect.
The first topography-guided systems were approved in the United States in 2013, 9,10 15 years after the first topography-guided system CE market approval in Europe. 11 There are now three systems approved in the United States, 12 but these approvals are all restricted to treating virgin eyes. Therapeutic corneal refractive surgery can only be done off-label, and treatments are restricted due to software locks and design limitations. Due to the relatively small market for therapeutic to- Guest Editorial pography-guided treatments, the expense of a trial and the difficulty in designing studies to clearly demonstrate safety and effectiveness in a diverse patient pool, FDA approval for these treatments is not likely to be undertaken by any company any time soon.
Unfortunately, FDA approval for PTK faces similar challenges. The first excimer laser FDA trials were for PTK alone for treating corneal scars and dystrophies 13 because this was required to demonstrate safety of the excimer laser before starting trials for refractive correction. However, few later generation lasers have obtained approval for PTK due to the prohibitive costs associated with obtaining separate FDA premarket approval. This has resulted in PTK, one of the most powerful therapeutic tools, not being directly available on many of the FDA-approved modern excimer lasers; surgeons are left to use indirect, expensive work-arounds such as balanced myopic/hyperopic treatments to achieve similar effects on these lasers.
Of course, several manufacturers have obtained FDA approval for excimer laser platforms for primary refractive procedures in the United States because these procedures are supported by large markets with significant commercial potential. Now, given the international success of both therapeutic topography-guided and PTK treatments, the extensive peer-review literature documenting outcomes, and the longstanding use of excimer lasers for refractive treatments, it seems reasonable that the FDA should create a viable regulatory pathway for U.S. surgeons to access these time-proven treatments. It would seem reasonable for PTK to be automatically approved as part of a refractive premarket approval, given the inherently obvious safety of a uniform depth ablation profile and the well-established therapeutic applications for corneal dystrophies, 14, 15 as well as refractive surgery complications.
Geography currently limits the overall safety of refractive surgery because of a surgeon's inability to use contemporary therapeutic refractive surgical tools. The FDA's Center for Devices has the opportunity to critically evaluate the approval process for therapeutic applications on already-approved medical devices to better align with its mission of promoting public health and its vision to provide patients access to safe and effective medical devices "first in the world." 16 This might be achieved by adopting recent initiatives to leverage real-world evidence to more efficiently balance premarket and postmarket data collection. The benefit and risk assessment of necessary therapeutic treatments for rare cases compared to elective treatment for millions of primary cases should rely on currently available clinical evidence to benefit patients and facilitate innovation. I look forward to the progress and actions proposed at the FDA to expedite the fulfilment of this need.
